We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fortive Plans to Buy Johnson & Johnson's Sterilization Unit
Read MoreHide Full Article
Fortive Corporation (FTV - Free Report) has recently made a proposal to Johnson & Johnson (JNJ - Free Report) to acquire its business unit of Advanced Sterilization Products (“ASP”) from its subsidiary, Ethicon, Inc..
ASP offers infection prevention solutions that are used in disinfection and sterilization of reusable surgical instruments. The solutions are based on low-temperature hydrogen peroxide sterilization technology and help in protecting patients from hospital infections. Last year, it generated $775 million of revenues.
Fortive has made a binding cash offer of $2.7 billion to purchase the business, which the company is likely to finance through available cash, equity and debt.
With the latest move, the company will be able to foray into the rapidly growing infection control market. Per the data from Markets and Markets, the market is expected to grow at a CAGR of 6.5% between 2017 and 2022 and reach 21.06 billion by 2022 from $15.35 billion in 2017.
Coming to the price performance, shares of Fortive have returned 17.7% over a year, outperforming the industry’s rally of 12%.
Expanding Product Portfolio
The ASP deal will help the company to expand its product portfolio. The products of ASP are STERRAD, EVOTECH and ENDOCLENS, which have gained popularity in the global market.
We believe the company is well poised to gain from the acquisition and the market in which ASP operates along with its own products namely Gilbarco Veeder-Root, Fluke, Sensing technologies, Tektronix, Qualitrol and Jacobs Vehicle Systems.
Notably, all of these products performed well in the last reported quarter and are expected to sustain the performance of Fortive across its geographical regions.
Strategic Deals Continues to Aid Growth
Strategic acquisitions and other deals have significantly contributed to Fortive’s growth trajectory by expanding its product portfolio. The company expects the buyout of ASP to be accretive like its other previous acquisitions.
Recently, the company signed a definitive agreement for combining four units of Automation & Specialty platform with Altra Industrial Motion, which will enhance its portfolio.
Additionally, the company’s acquisitions of Orpak, Industrial Scientific, eMaint and Landauer. have been aiding the segmental and regional performance of the company in every quarter since then.
We note that these deals will continue to help the company in gaining momentum in the market by improving its customer base. This will aid Fortive’s top-line growth.
Long-term earnings growth rate for TE Connectivity and AMETEK is pegged at 10.94% and 10%, respectively.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Fortive Plans to Buy Johnson & Johnson's Sterilization Unit
Fortive Corporation (FTV - Free Report) has recently made a proposal to Johnson & Johnson (JNJ - Free Report) to acquire its business unit of Advanced Sterilization Products (“ASP”) from its subsidiary, Ethicon, Inc..
ASP offers infection prevention solutions that are used in disinfection and sterilization of reusable surgical instruments. The solutions are based on low-temperature hydrogen peroxide sterilization technology and help in protecting patients from hospital infections. Last year, it generated $775 million of revenues.
Fortive has made a binding cash offer of $2.7 billion to purchase the business, which the company is likely to finance through available cash, equity and debt.
With the latest move, the company will be able to foray into the rapidly growing infection control market. Per the data from Markets and Markets, the market is expected to grow at a CAGR of 6.5% between 2017 and 2022 and reach 21.06 billion by 2022 from $15.35 billion in 2017.
Coming to the price performance, shares of Fortive have returned 17.7% over a year, outperforming the industry’s rally of 12%.
Expanding Product Portfolio
The ASP deal will help the company to expand its product portfolio. The products of ASP are STERRAD, EVOTECH and ENDOCLENS, which have gained popularity in the global market.
We believe the company is well poised to gain from the acquisition and the market in which ASP operates along with its own products namely Gilbarco Veeder-Root, Fluke, Sensing technologies, Tektronix, Qualitrol and Jacobs Vehicle Systems.
Notably, all of these products performed well in the last reported quarter and are expected to sustain the performance of Fortive across its geographical regions.
Strategic Deals Continues to Aid Growth
Strategic acquisitions and other deals have significantly contributed to Fortive’s growth trajectory by expanding its product portfolio. The company expects the buyout of ASP to be accretive like its other previous acquisitions.
Recently, the company signed a definitive agreement for combining four units of Automation & Specialty platform with Altra Industrial Motion, which will enhance its portfolio.
Additionally, the company’s acquisitions of Orpak, Industrial Scientific, eMaint and Landauer. have been aiding the segmental and regional performance of the company in every quarter since then.
We note that these deals will continue to help the company in gaining momentum in the market by improving its customer base. This will aid Fortive’s top-line growth.
Fortive Corporation Revenue (TTM)
Fortive Corporation Revenue (TTM) | Fortive Corporation Quote
Zacks Rank & Stocks to Consider
Currently, Fortive carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader technology sector are TE Connectivity (TEL - Free Report) and AMETEK (AME - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth rate for TE Connectivity and AMETEK is pegged at 10.94% and 10%, respectively.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>